Exelixis stock price target lowered to $45 at RBC on lifecycle cuts

Published 29/07/2025, 18:18
Exelixis stock price target lowered to $45 at RBC on lifecycle cuts

Investing.com - RBC Capital has lowered its price target on Exelixis (NASDAQ:EXEL) to $45.00 from $50.00 while maintaining a Sector Perform rating following the company’s second-quarter earnings report. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company maintaining a "GREAT" financial health score and an impressive 92% return over the past year.

The biopharmaceutical company missed revenue expectations in its 2Q25 results, which RBC analyst Leonid Timashev suggests may contribute to near-term weakness in the stock price.

A key factor in RBC’s price target reduction was Exelixis’s decision to discontinue development of its zanza drug in head and neck squamous cell carcinoma (HNSCC), potentially limiting the drug’s ability to support revenues after Cabometyx loses exclusivity in 2030.

Despite the disappointing quarterly performance, RBC noted that uptake remained strong for Cabometyx in neuroendocrine tumors (NETs), which could drive continued growth supporting full-year 2025 financial results.

RBC believes the current share price fairly values Cabometyx’s remaining growth potential, zanza’s lifecycle, and the upcoming STELLAR-303 metastatic colorectal cancer data, expecting the stock to trade within its current range until there is further clarity on product lifecycle development.

In other recent news, Exelixis reported its second-quarter 2025 earnings, revealing an earnings per share (EPS) of $0.75, which exceeded analysts’ expectations of $0.64. The company’s revenue for the quarter reached $568 million, slightly below the anticipated $578.46 million. Truist Securities responded by lowering its price target for Exelixis to $49 from $56, citing mixed results, particularly the Cabometyx sales of $520 million, which fell short of Wall Street’s $530 million estimate. Despite the revenue miss, JMP Securities maintained its Market Outperform rating and a $50 price target, attributing the sales shortfall to new pricing dynamics but noting strong volume growth of 18% year-over-year. Stifel, on the other hand, raised its price target for Exelixis to $41 from $38, reflecting increased success probabilities for the zanza treatment in metastatic colorectal cancer. These developments highlight a mixed but optimistic outlook for Exelixis, with analysts focusing on strategic advancements and potential growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.